SCHEMBL20183500

SCHEMBL20183500

COc1ccccc1NCc1ccc(-c2cccc(C(=O)O)c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.57
MAPT P10636 3/20 0.57
HPGD P15428 3/20 0.57
KDM4E B2RXH2 2/20 0.57
ALDH1A1 P00352 2/20 0.57
LMNA P02545 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
LTB4R Q15722 2/20 0.55
ACLY P53396 1/20 0.55
MEN1 O00255 1/20 0.54
EPHX2 P34913 1/20 0.52
NR1H4 Q96RI1 1/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
SIRT2 Q8IXJ6 1/20 0.52
HDAC1 Q13547 2/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
PPARG P37231 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20183707 0.81 PPARA (0.65) KMT2AMEN1NPC1RAB9APPARA
SCHEMBL20183490 0.80 PPARA (0.66) KMT2AHPGDKDM4EALDH1A1LMNA
SCHEMBL20183499 0.79 EPHX2 (0.62) KMT2AMEN1EPHX2NR1H4HDAC1
SCHEMBL15854547 0.78 HDAC8 (0.60) ACLYEPHX2NR1H4HDAC1HDAC8
SCHEMBL10055049 0.77 ALDH1A1 (0.55) KMT2AMAPTHPGDKDM4EALDH1A1
SCHEMBL15761720 0.77 CA1 (0.60) KMT2AMAPTHPGDALDH1A1LMNA
SCHEMBL22000063 0.76 MAPT (0.81) KMT2AMAPTHPGDKDM4EALDH1A1
SCHEMBL15761754 0.76 HIF1A (0.58) KMT2AMAPTHPGDALDH1A1L3MBTL1
SCHEMBL2877032 0.76 GBA1 (0.57) KMT2AMAPTHPGDKDM4EALDH1A1
SCHEMBL28629373 0.76 HPGD (0.54) HPGDALDH1A1LTB4REPHX2NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3327001-B1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT UNIV DONGGUK IND ACAD COOP (KR) 2022-04-13 EP disclosed
US-20180215706-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2018-08-02 US disclosed
EP-3327001-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT Dongguk University Industry-Academic Cooperation Foundation (KR) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215706-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT LTB4R2, CYSLTR2, LTB4R KMT2A 1026/4885MAPT 969/4885HPGD 1789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.